NCT04796012: VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 23 planned
- Started
- 18 Apr 2023
- Primary completion
- Jan 2027
- Arms
- Feasibility Cohort: Patients with relapsed or refractory solid tumors, Rhabdomyosarcoma (RMS) Cohort: Patients with rhabdomyosarcoma
- Results
- None posted
- 12 Mar 2021: Trial registered
- 18 Apr 2023: Trial started